SUMMARY An evaluation of the diagnostic value of low avidity antibodies to double stranded DNA (dsDNA) measured by the polyethylene glycol (PEG) assay was undertaken. By routine screening low avidity anti-dsNDA were detected in the serum samples of 106 hitherto unknown patients. Clinical data of these patients were collected and when only low avidity anti-dsDNA was present (n=92) a varied disease spectrum was observed. A diagnosis of systemic lupus erythematosus (SLE) was established in 48/92 (52%), lupus-like disease in 21/92 (23%), autoimmune hepatitis in 9/92 (10%), rheumatoid arthritis in 8/92 (9%), and mixed connective tissue disease in 2/92 (2%) of all patients. Patients with definite SLE were all older than 45 years and predominantly female (46/48, 96%). They showed a remarkably low incidence of renal disease (2/69, 3%). When high avidity antibodies to dsDNA as measured by the Farr assay were present as well (n=14) a diagnosis of SLE could be established in 12/14 (86%) of all patients, indicating the secondary importance of low avidity anti-dsDNA in these patients.
Antibodies to double stranded DNA (dsDNA) are thought to play a part in the pathogenesis of systemic lupus erythematosus (SLE). 1-3 The precise mechanism by which they contribute to tissue damage is a subject of discussion. Deposits of circulating immune complexes" and in situ formation of dsDNA/anti-dsDNA7-10 immune complexes always seemed valid explanations, but anti-dsDNA antibodies are heterogeneous and differ with respect to (sub)class, specificity, complement fixing ability, and avidity." 12 Nowadays, there are several methods of detecting antibodies to dsDNA.'3 14 The main difference between such assays lies in their ability to detect antibodies to dsDNA with varying degrees of avidity. 15 A clear relation has repeatedly been shown between high avidity antibodies detected by the Farr assay and disease activity.'6-'8 The role of low avidity antibodies has remained relatively uncertain,1 some reports showing a relation with a less fulminant form of SLE.20 Therefore we undertook a study to evaluate the diagnostic significance of low avidity antibodies to dsDNA.
Accepted for publication 27 January 1989. Correspondence to Dr J C Nossent, Dr After incubation of the mixture for one hour at 37°C 5 ml of a cold 50% saturated ammonium sulphate solution was added. The precipitate was allowed to form for 30 minutes at 4°C, after which it was pelleted by centrifugation for 15 minutes at 3000 g. The precipitate was washed twice with 50% saturated ammonium sulphate and, finally, dissolved in 1 ml of Soluene-100 (Packard). After addition of 10 ml scintillation fluid (Instafluor 11, Packard) the radioactivity was measured. The mean (SD) binding of 150 normal control sera was 5 (3)%. Units are defined as stated under the PEG assay.
ANTI-DNA AVIDITY
As antibodies to ds-DNA vary widely in their avidity towards DNA we used two assays to discriminate between patients on the basis of their anti-DNA avidity. As has been shown before the Faff assay is strictly selective for high avidity anti-DNA, whereas the PEG assay allows for the simultaneous measurement of low and high avidity anti-DNA. 24 (Table 3) .
ANTI-dsDNA TITRES figure 1 shows anti-dsDNA values by PEG assay for group I patients. Lower titres were found for patients with lupus-like disease (mean (SD) 41-2 (23-2) U/ml) and mixed connective tissue disease (mean (SD) 13-0 (19-2) U/ml) than for patients with SLE, whereas patients with other diseases had similar titres. Levels of anti-dsDNA by PEG assay 26 27 We found little correlation between titres of low avidity antibodies to dsDNA and the different ,an (SD) 111-2 diseases. Patients with lupus-like disease (a eels in group I prodrome or a mitigated form of SLE?) and mixed 4 (117) U/ml), connective tissue disease had lower values, and ssay in group II although no definite conclusion can be drawn from 3 (1985) U/ml) these data, it seems that the low avidity character of these patients anti-dsDNA, rather than its level, is important in the diagnosis.
In conclusion, we studied the diagnostic value of low avidity antibodies to dsDNA and our results indicate that when only low avidity antibodies to at a significant dsDNA are found a spectrum of autoimmune on testing for disease is present and SLE can be diagnosed in escence in the about 50% of these patients. These patients which on subsequent SLE are all elderly (>45 years) and predominantly crepancy is ex-female (95%), and they have a remarkably low have antibodies incidence of renal disease. When high avidity lissociated from antibodies are present as well a diagnosis of SLE can be made in 86% of the cases, leaving only a minor role for low avidity antibodies to dsDNA in this setting.
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